SCHEMBL25285293

SCHEMBL25285293

Cc1cc(-c2ccc([N+](=O)[O-])c(OCc3ccc(F)cc3)c2)c(C#N)c(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.41
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ATM Q13315 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
XDH P47989 2/20 0.38
CNR1 P21554 1/20 0.37
SQOR Q9Y6N5 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP19A1 P11511 2/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CHEK1 O14757 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25245621 0.88 SQOR (0.46) PTGESTDP1L3MBTL1ALDH1A1MAPT
SCHEMBL25240871 0.88 MEN1 (0.43) PTGESL3MBTL1ALDH1A1XDHCNR1
SCHEMBL25240568 0.85 KDM4E (0.43) TDP1L3MBTL1ATMALDH1A1MAPT
SCHEMBL30566184 0.81 PTGES (0.39) PTGESALDH1A1XDHHTTCYP19A1
SCHEMBL25236663 0.81 PTGES (0.39) PTGESALDH1A1XDHHTTCYP19A1
SCHEMBL25283297 0.79 NPC1 (0.41) PTGESXDHCNR1NPC1RAB9A
SCHEMBL25239664 0.79 CYP19A1 (0.39) TDP1L3MBTL1XDHCNR1SQOR
SCHEMBL25244654 0.76 ATM (0.50) PTGESATMALDH1A1MAPTHTT
SCHEMBL30566216 0.76 ATM (0.50) PTGESATMALDH1A1MAPTHTT
SCHEMBL30917005 0.73 IKBKB (0.52) ATMALDH1A1MAPTRAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 US disclosed
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-02-20 US disclosed
EP-4452977-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 EP disclosed
EP-4452978-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 EP disclosed
WO-2023115142-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed
WO-2023115150-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 PTGES 2804/4885TDP1 376/4885L3MBTL1 440/4885
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 PTGES 1923/4885TDP1 373/4885L3MBTL1 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.